Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types, including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT, in San Francisco.
舊金山，2025年1月6日（環球新聞）-- Nurix Therapeutics, Inc.（納斯達克：NRIX）是一家臨牀階段的生物製藥公司，開發旨在治療癌症和炎症疾病的靶向蛋白調節藥物，今天宣佈其總裁兼首席執行官Arthur T. Sands萬.D.，Ph.D.將於2025年1月13日星期一下午3:00在舊金山舉行的第43屆J.P.摩根醫療健康大會上進行公司更新演講。
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
該活動將進行現場網絡直播，投資者可通過Nurix網站的投資者部分中的鏈接訪問。活動結束後，存檔的網絡直播將在30天內提供。
About Nurix Therapeutics, Inc.
關於Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types, including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .
Nurix Therapeutics是一家臨牀階段的生物製藥公司，專注於發現、開發和商業化基於細胞蛋白水平調節的小分子和抗體療法，作爲癌症、炎症性疾病和其他棘手疾病的新穎治療方法。Nurix利用在E3連接酶領域的廣泛專業知識以及專有的DNA編碼庫，建立了一種集成的發現平台，以識別和推進針對E3連接酶的新藥候選物，E3連接酶是一類廣泛的酶，能夠調節細胞內的蛋白質。Nurix的藥物發現方法是利用或抑制E3連接酶在泛素-蛋白酶體系統中的自然功能，以選擇性地降低或提高細胞蛋白水平。Nurix完全擁有的臨牀階段管道包括針對布魯頓酪氨酸激酶的靶向蛋白降解劑（B細胞信號蛋白）和Casitas B譜系淋巴瘤原癌基因B的抑制劑（E3連接酶，調節多種免疫細胞類型的激活，包括T細胞和NK細胞）。Nurix的總部位於加利福尼亞州舊金山。欲了解更多信息，請訪問。
Contacts:
聯繫方式：
Investors
投資者
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
傑森·坎托爾，博士。
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
伊麗莎白·沃爾夫博士
惠爾豪斯生命科學顧問
lwolffe@wheelhouselsa.com
Media
媒體
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
阿爾賈奈·雷諾茲
惠爾豪斯生命科學顧問
areynolds@wheelhouselsa.com
譯文內容由第三人軟體翻譯。
